Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/99845
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Grossmann, M. | - |
dc.contributor.author | Hoermann, R. | - |
dc.contributor.author | Wittert, G. | - |
dc.contributor.author | Yeap, B. | - |
dc.date.issued | 2015 | - |
dc.identifier.citation | Clinical Endocrinology, 2015; 83(3):344-351 | - |
dc.identifier.issn | 0300-0664 | - |
dc.identifier.issn | 1365-2265 | - |
dc.identifier.uri | http://hdl.handle.net/2440/99845 | - |
dc.description.abstract | Context: The effects of testosterone treatment on glucose metabolism and other outcomes in men with type 2 diabetes (T2D) and/or the metabolic syndrome are controversial. Objective: To perform a systematic review and meta-analysis of placebo-controlled double-blind randomized controlled clinical trials (RCT) of testosterone treatment in men with T2D and/or the metabolic syndrome. Data sources: A systematic search of RCTs was conducted using Medline, Embase and the Cochrane Register of controlled trials from inception to July 2014 followed by a manual review of the literature. Study selection: Eligible studies were published placebo-controlled double-blind RCTs published in English. Data extraction: Two reviewers independently selected studies, determined study quality and extracted outcome and descriptive data. Data synthesis: Of the 112 identified studies, seven RCTs including 833 men were eligible for the meta-analysis. In studies using a simple linear equation to calculate the homeostatic model assessment of insulin resistance (HOMA1), testosterone treatment modestly improved insulin resistance, compared to placebo, pooled mean difference (MD) −1·58 [−2·25, −0·91], P < 0·001. The treatment effect was nonsignificant for RCTs using a more stringent computer-based equation (HOMA2), MD −0·19 [−0·86, 0·49], P = 0·58). Testosterone treatment did not improve glycaemic (HbA1c) control, MD −0·15 [−0·39, 0·10], P = 0·25, or constitutional symptoms, Aging Male Symptom score, MD −2·49 [−5·81, 0·83], P = 0·14). Conclusions: This meta-analysis does not support the routine use of testosterone treatment in men with T2D and/or the metabolic syndrome without classical hypogonadism. Additional studies are needed to determine whether hormonal interventions are warranted in selected men with T2D and/or the metabolic syndrome. | - |
dc.description.statementofresponsibility | Mathis Grossmann, Rudolf Hoermann, Gary Witter and Bu B. Yeap | - |
dc.language.iso | en | - |
dc.publisher | Wiley-Blackwell | - |
dc.rights | © 2014 John Wiley & Sons Ltd | - |
dc.source.uri | http://dx.doi.org/10.1111/cen.12664 | - |
dc.subject | Metabolic syndrome | - |
dc.title | Effects of testosterone treatment on glucose metabolism and symptoms in men with type 2 diabetes and the metabolic syndrome: a systematic review and meta-analysis of randomized controlled clinical trials | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1111/cen.12664 | - |
dc.relation.grant | http://purl.org/au-research/grants/nhmrc/1024139 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Wittert, G. [0000-0001-6818-6065] | - |
Appears in Collections: | Aurora harvest 7 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.